RAIA DROGASIL SA

Location

SAO PAULO

Founded

1935-03-28

Website

https://www.drogasil.com.br

Risk Signals

714 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Drug Stores and Proprietary Stores), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Filter risk signals by topic

Select a theme below to explore the company’s news mentions in specific risk areas.

Business Launches (107) Financial Reporting (90) Business Growth Initiatives (79) Earnings Reports & Warnings (75) Stock Market Events (66) Investment Strategies (58) Recruitment Activities (57) Inter-Organizational Collaborations (57) Acquisition Announcements (51) Legal Proceedings (37) Issuing Shares (27) New Product Release (27) Public Health Crisis Response (26) Merger Announcements (23) Market Trends (22) Capital Funding Requests (22) Workforce Reductions (21) Access and Affordability Initiatives (21) Employee Safety & Health (20) Shareholders Feedback (18) Executive Leadership Changes (16) Regulatory Penalties (16) Environmental Assessments (16) Sustainable Practices (15) Business Resilience Planning (13) Price Reductions (13) Credit Rating Updates (12) Tech Innovation & Advancements (12) Stock Buyback (11) Cultural Trends and Innovations (11)

Recent Articles about RAIA DROGASIL SA

Live alerts from global media, monitored by Business Radar

2025-04-11 (exame.com)

No bargain and good choices: the lessons of Bartunek and Behring in investments (and in life) | Insight

At Brazil Conference, CEOs from Constellation and 3G Capital explain why the long -term vision and the choice of good companies are worth more than the search for bargain

2025-01-28 (acionista.com.br)

Morgan Stanley indicates Raia Drogasil (Radl3) as a good investment option

The Brazilian financial market is going through decisive moments, especially in relation to the health sector and pharmacies. The Morgan Stanley, one of the main investment banks, reiterated its overweight recommendation for the actions of Raia Drogasil (RADL3), establishing a target price of $ 30, even in a unfavorable news scenario and uncertainties in [… ]